Clinical trial
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
NCT00101829 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00101829 |
|---|---|
| Title | Anti-CD20 Antibody Therapy for Sjogren's Syndrome |
| Official title | An Open-Label, One Arm, Phase I Safety Study of Anti-CD20 Antibody (Rituximab, Rituxan) Therapy in the Treatment of Primary Sjogren's Syndrome |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Autoimmunity Centers of Excellence |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Sjogren's Syndrome |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 12 |
| Start date | Apr 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2009 |
| First posted | Jan 14, 2005 |
| Last update posted | Oct 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: